
 НОМЕ	QUESTIONS	JOBS	Search		41 3 1	Add new
		Prolonged Release (PR) Compared ed, Open-label, Phase 3b/4 Trial	with Oxycodone/Naloxone PR in Patients	with Seve	ere Chronic Low Back Pain	

Article in Pain Practice 16(5) · November 2015

DOI: 10.1111/papr.12361



Show more authors

Abstract

Objective

To evaluate tolerability, safety, and quality-of-life outcomes in non-opioid-pretreated patients with severe chronic low back pain with a neuropathic component receiving tapentadol PR vs. oxycodone/naloxone PR.

Methods

Eligible patients (average pain intensity [numerical rating scale] ≥ 6; painDETECT positive/unclear ratings) were randomized to twice-daily tapentadol PR 50 mg or oxycodone/naloxone PR 10 mg/5 mg. After a 21-day titration (maximum twice-daily doses: tapentadol PR 250 mg, or oxycodone/naloxone PR 40 mg/20 mg plus oxycodone PR 10 mg), target doses were continued for 9 weeks. Change in the Patient Assessment of Constipation Symptoms (PAC-SYM) total score from baseline to final evaluation was a primary endpoint.

Results

For the primary tolerability-related endpoint, the 97.5% exact repeated confidence interval for tapentadol PR minus oxycodone/naloxone PR for the PAC-SYM total score was [-0.259, 0.121], showing noninferiority (upper limit < 0.7). Incidences of constipation and vomiting were significantly lower with tapentadol PR than oxycodone/naloxone PR ($P \le 0.045$). Confirmatory superiority based on formal noninferiority was shown for the primary effectiveness endpoint (change from baseline to final evaluation in pain intensity) for tapentadol PR vs. oxycodone/naloxone PR (presented separately). Improvements in the Short Form-12 physical component summary and EuroQol-5 Dimension health status index and health state assessment were significantly greater with tapentadol PR vs. oxycodone/naloxone PR ($P \le 0.024$).

Conclusions

Tapentadol PR had a minimal impact on bowel function (noninferior to oxycodone/naloxone PR) and, along with superior effectiveness (presented separately), was associated with significantly lower incidences of constipation and vomiting and significant improvements in quality-of-life measures vs. oxycodone/naloxone PR.

You've requested the full-text version from the authors.

We'll notify you when they provide the full-text.

Full-text requested

1 of 3 7/30/16 1:40 PM

See all > tions 16 Reads		as publications directly with the y adding your comments here.	authors			Following	Pull-text requested
itations 0 Ref	erences 41 Comm	nents Add yours					
Full-text Article · Au	ug 2014 · Clinical Therapeutics	l Prolonged Release for the Ma					
Manuel J. Sánchez o	del Águila 🏻 Michael Schen	k স Kai-Uwe Kern +1 more a	uuthor Ilona S	0 Comments	10 Citations		
Article · Jul 2009 · Drugs	of today (Barcelona, Spain: 1998				olecule		
Thomas M Tzschent Request full-text	ke Wulrich Jahnel W	Babette Kogel +9 more authors	Regina Kleiner	0 Comments	68 Citations		
Prevalence of chronic		acteristics in the general popul	ation. Pain 136: 380	-387			
Didier Bouhassira Read full-text	Michel Lantéri-Minet	Nadine Attal +1 more author	Chantal Toubou	0 Comments	535 Citations		
1)		nduced Bowel Dysfunction: Res	ults of a US and Euro	opean Patient Surv	ey (PROBE		
Article · Sep 2008 · Pain M Timothy J Bell Request full-text		ne Miaskowski +2 more authors	Russell Willia	mson 0 Comments	169 Citations		
-	on of a Constipation Sympt	om Assessment Questionnaire					
L. Frank, L. Kleinmar				0 Comments	74 Citations		
Kalso E, Edwards JE, M	Moore RA, et al. Opioids in c	hronic non-cancer pain: systen	natic review of effic	acy and safety			
Eija Kalso Jag	yne E Edwards R Andrew	Moore		0 Comments	665 Citations		

2 of 3 7/30/16 1:40 PM

See all > ns 16 Reads		Following	Full-text requested
Read full-text	0 Comments 97 Citation	ns	
Nausea and Vomiting Side Effects with Opioid Analgesics during Treatment of Chro Management Options	nic Pain: Mechanisms, Implications, and		
Full-text Article · Apr 2009 · Pain Medicine			
Rank Porreca Michael H Ossipov			
Read full-text	0 Comments 68 Citation	ns	
	k pain with or without a neuropathic pain		
component: Results of an open-label, phase 3b study	k pain with or without a neuropathic pain		
Effectiveness and safety of tapentadol prolonged release for severe, chronic low bac component: Results of an open-label, phase 3b study Article · Mar 2012 · Current Medical Research and Opinion Illona Steigerwald Matthias Müller Anthony Davies +6 more authors	k pain with or without a neuropathic pain Hans G Kress		
component: Results of an open-label, phase 3b study Article · Mar 2012 · Current Medical Research and Opinion		ns	
component: Results of an open-label, phase 3b study Article · Mar 2012 · Current Medical Research and Opinion Ilona Steigerwald Matthias Müller Anthony Davies +6 more authors Request full-text	Hans G Kress	ns	
component: Results of an open-label, phase 3b study Article · Mar 2012 · Current Medical Research and Opinion Ilona Steigerwald Matthias Müller Anthony Davies +6 more authors Request full-text	Hans G Kress	ns	
component: Results of an open-label, phase 3b study Article · Mar 2012 · Current Medical Research and Opinion Ilona Steigerwald Matthias Müller Anthony Davies +6 more authors Request full-text Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment Full-text Article · Aug 2010 · The Lancet Neurology	Hans G Kress	ns	
Article · Mar 2012 · Current Medical Research and Opinion Ilona Steigerwald	Hans G Kress		
Article · Mar 2012 · Current Medical Research and Opinion Ilona Steigerwald Matthias Müller Anthony Davies +6 more authors Request full-text Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment Full-text Article · Aug 2010 · The Lancet Neurology Ralf Baron Andreas Binder Gunnar Wasner	Hans G Kress 0 Comments 37 Citation	118	
Article · Mar 2012 · Current Medical Research and Opinion Ilona Steigerwald	Hans G Kress 0 Comments 37 Citation 0 Comments 455 Citation Show more	ns factor and	

3 of 3 7/30/16 1:40 PM